Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors (NCT06082960)
🩺 Plain-English Summary (8th-Grade Level)
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors
Who can join: Review the eligibility criteria below.
Location: Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
- SCRI Oncology Partners — Nashville, Tennessee
- NEXT Oncology — San Antonio, Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- University Health Network, Princess Margaret Cancer Centre — Toronto,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.